Home > Publications database > Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers. > print

001     291071
005     20241218133611.0
024 7 _ |a 10.1186/s13073-024-01357-w
|2 doi
024 7 _ |a pmid:38886830
|2 pmid
024 7 _ |a altmetric:164629615
|2 altmetric
037 _ _ |a DKFZ-2024-01291
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Krieg, Stephan
|0 P:(DE-He78)9ea61053e4bed51c6256fe19a0559868
|b 0
|e First author
|u dkfz
245 _ _ |a Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers.
260 _ _ |a London
|c 2024
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1718719259_17670
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:F190#LA:F190#
520 _ _ |a Somatic copy number alterations are a hallmark of cancer that offer unique opportunities for therapeutic exploitation. Here, we focused on the identification of specific vulnerabilities for tumors harboring chromosome 8p deletions.We developed and applied an integrative analysis of The Cancer Genome Atlas (TCGA), the Cancer Dependency Map (DepMap), and the Cancer Cell Line Encyclopedia to identify chromosome 8p-specific vulnerabilities. We employ orthogonal gene targeting strategies, both in vitro and in vivo, including short hairpin RNA-mediated gene knockdown and CRISPR/Cas9-mediated gene knockout to validate vulnerabilities.We identified SLC25A28 (also known as MFRN2), as a specific vulnerability for tumors harboring chromosome 8p deletions. We demonstrate that vulnerability towards MFRN2 loss is dictated by the expression of its paralog, SLC25A37 (also known as MFRN1), which resides on chromosome 8p. In line with their function as mitochondrial iron transporters, MFRN1/2 paralog protein deficiency profoundly impaired mitochondrial respiration, induced global depletion of iron-sulfur cluster proteins, and resulted in DNA-damage and cell death. MFRN2 depletion in MFRN1-deficient tumors led to impaired growth and even tumor eradication in preclinical mouse xenograft experiments, highlighting its therapeutic potential.Our data reveal MFRN2 as a therapeutic target of chromosome 8p deleted cancers and nominate MFNR1 as the complimentary biomarker for MFRN2-directed therapies.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Chromosome 8p deletion
|2 Other
650 _ 7 |a MFRN1/2 paralog buffering
|2 Other
650 _ 7 |a SCNAs
|2 Other
650 _ 7 |a Synthetic lethality
|2 Other
650 _ 7 |a Mitochondrial Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Chromosomes, Human, Pair 8: genetics
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Chromosome Deletion
|2 MeSH
650 _ 2 |a Neoplasms: genetics
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
650 _ 2 |a Synthetic Lethal Mutations
|2 MeSH
650 _ 2 |a Mitochondria: metabolism
|2 MeSH
650 _ 2 |a Mitochondria: genetics
|2 MeSH
650 _ 2 |a Mitochondrial Proteins: genetics
|2 MeSH
650 _ 2 |a Mitochondrial Proteins: metabolism
|2 MeSH
650 _ 2 |a Gene Expression Regulation, Neoplastic
|2 MeSH
650 _ 2 |a DNA Copy Number Variations
|2 MeSH
700 1 _ |a Rohde, Thomas
|b 1
700 1 _ |a Rausch, Tobias
|b 2
700 1 _ |a Butthof, Luise
|0 P:(DE-He78)6532f23ad58d8995fb01cff4c2a7253f
|b 3
|u dkfz
700 1 _ |a Wendler-Link, Lena
|0 P:(DE-He78)0f72fbdfdd9ecf3bd83c82ce21d318eb
|b 4
|u dkfz
700 1 _ |a Eckert, Christoph
|0 P:(DE-He78)f85c49f6fe015e7fcd4bf6e76de7040d
|b 5
700 1 _ |a Breuhahn, Kai
|b 6
700 1 _ |a Galy, Bruno
|0 P:(DE-He78)00eb6e35f6edc7e5fcb2aacc7a21f891
|b 7
|u dkfz
700 1 _ |a Korbel, Jan
|b 8
700 1 _ |a Billmann, Maximilian
|b 9
700 1 _ |a Breinig, Marco
|0 P:(DE-He78)a7f6241ee41dbfd09892f8027db893d0
|b 10
|u dkfz
700 1 _ |a Tschaharganeh, Darjus Felix
|0 P:(DE-He78)ceccc9aed8c6e89c00795bce1f1d83a3
|b 11
|e Last author
|u dkfz
773 _ _ |a 10.1186/s13073-024-01357-w
|g Vol. 16, no. 1, p. 83
|0 PERI:(DE-600)2484394-5
|n 1
|p 83
|t Genome medicine
|v 16
|y 2024
|x 1756-994X
856 4 _ |u https://inrepo02.dkfz.de/record/291071/files/s13073-024-01357-w.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/291071/files/s13073-024-01357-w.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:291071
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)9ea61053e4bed51c6256fe19a0559868
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)6532f23ad58d8995fb01cff4c2a7253f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)0f72fbdfdd9ecf3bd83c82ce21d318eb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)f85c49f6fe015e7fcd4bf6e76de7040d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)00eb6e35f6edc7e5fcb2aacc7a21f891
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)a7f6241ee41dbfd09892f8027db893d0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)ceccc9aed8c6e89c00795bce1f1d83a3
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GENOME MED : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:07:38Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:07:38Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-05-02T09:07:38Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b GENOME MED : 2022
|d 2023-08-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-25
920 2 _ |0 I:(DE-He78)F190-20160331
|k F190
|l NWG Cell Plasticity and Epigenetic Remodeling
|x 0
920 1 _ |0 I:(DE-He78)F190-20160331
|k F190
|l NWG Cell Plasticity and Epigenetic Remodeling
|x 0
920 1 _ |0 I:(DE-He78)D430-20160331
|k D430
|l Virus-assoziierte Karzinogenese
|x 1
920 0 _ |0 I:(DE-He78)F190-20160331
|k F190
|l NWG Cell Plasticity and Epigenetic Remodeling
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F190-20160331
980 _ _ |a I:(DE-He78)D430-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21